Novartis announces data in Neurology reinforcing the real-world and long-term effectiveness and safety of Aimovig® as a preventive treatment across the full spectrum of migraine

  • Real-world evidence supports benefits seen in Aimovig clinical trials
     
  • Open-label data highlight long-term efficacy and safety profile of Aimovig in episodic and chronic migraine
     
  • Post-hoc and real-world data show preventive treatment with Aimovig significantly reduces need for acute medications
     
  • These additional long-term data complement the position of Aimovig as the most prescribed anti-CGRP, with more than 350,000 patients prescribed worldwide since launch1 …
/by